Meagan Parrish from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting		Are orexins the next golden child of neuroscience? - 12 days ago As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D - 17 days ago What should pharma make of the FDA going dark on DEI? - 18 days ago Pharma’s forecast for 2025: Sowing seeds of a rebound - 22 days ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - about 1 month ago The ability to pivot will be ‘key’ as pharma’s tariff threat looms - about 1 month ago PharmaVoice’s Crystal Ball: The industry’s AI future - about 2 months ago 4 companies to watch in the accelerating gene editing race - about 2 months ago 3 closely watched drugs that failed in the clinic - 2 months ago Will the ‘anti-woke’ movement derail DEI efforts in pharma? - 2 months ago What’s next for 23andMe? - 2 months ago Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide - 3 months ago Trump’s tariffs could put more pressure on the U.S. to produce generic drugs. Are we ready? - 3 months ago The big rebrand: Why these 4 biopharmas changed their name this year - 3 months ago Note from the Editor-in-Chief - 3 months ago Can the girl power of Arrivo’s depression drug help reverse its fortunes? - 3 months ago Will Walgreens’ store closures derail its clinical trial aims? - 3 months ago The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - 3 months ago Where are they now? 4 biotechs that soared then crashed during the pandemic - 3 months ago Spravato is just the beginning in a new wave of depression meds - 3 months ago CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure - 4 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 4 months ago A sickle cell cure exists. But patients need more than just gene therapy. - 4 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 4 months ago On the front lines of the superbug war, new treatments can’t arrive soon enough - 4 months ago J&J’s comeback kid Spravato heads for blockbuster status - 4 months ago Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next? - 4 months ago 2024 PharmaVoice 100s: Patient Champions - 4 months ago Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with - 4 months ago Want to launch a blockbuster? An AstraZeneca exec breaks it down. - 4 months ago 2024 PharmaVoice 100s: Trailblazers - 4 months ago 2024 PharmaVoice 100s: Standout Leaders - 4 months ago BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s - 4 months ago An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - 5 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 5 months ago After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - 5 months ago Who’s winning in biotech’s tight market? - 5 months ago Why pharma should redefine ‘women’s health’ - 5 months ago What 3 layoff stories reveal about pharma’s troubles - 6 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 6 months ago Is anyone taking the world’s priciest drugs? - 6 months ago What pharma has learned from AI - 7 months ago Neuro drugs are still faltering, despite rising investment - 7 months ago Bird flu puts BARDA back in the spotlight - 7 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 7 months ago Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - 7 months ago Up-and-comers look for an edge in the bustling ADC field - 8 months ago Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll - 8 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 9 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 9 months ago